PeppiLibrary

Skin & Anti-aging

Argireline peptide reference

Topical hexapeptide that blunts facial muscle contraction. 'Botox in a bottle' marketing.

Last reviewed May 6, 2026 FDA-approved FDA approved
Peppi reviewing Argireline notes
Default dose label5 mg
Preferred routeTopical
Frequency label2× daily
Storage windowNot listed

Evidence snapshot

FDA-approved

Evidence maturityFDA approved
Cosmetic ingredient with peer-reviewed dermatology studies showing modest line-depth reduction

FDA-approved cosmetic ingredient

Route map

How records are usually labeled

1 Topical

Apply to specific expression-line areas; avoid mucous membranes.

Vial timeline

Storage cues to log

Before mixPer product label — usually room temperature; refrigeration extends shelf life.
After mixN/A — formulated product.
Use-by cueShelf life not listed
Mixed vial windowNot listed
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial label
Dose 5 mg
Route Topical
Review storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Argireline. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Argireline is a synthetic hexapeptide derived from a fragment of SNAP-25, mimicking its inhibition of catecholamine release at neuromuscular junctions. Topically applied, it reduces the depth of expression lines (forehead, crow's feet) by attenuating microcontractions of underlying mimic muscles. Effects are subtle compared to true botulinum toxin but accumulate over weeks of consistent use.

Also known as: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8.

Reduction of expression-line depthAnti-aging skincare adjunctLower-cost alternative for those avoiding injectables

Mechanism and timing snapshot

Mimics the N-terminal sequence of SNAP-25, competitively destabilising the SNARE complex and reducing acetylcholine release at neuromuscular junctions in the dermis. Effect is local, mild, and reversible.

Onset labelNot listed
Catalog onset field, when available.
Half-life labelNot listed
Topical formulation; systemic absorption is minimal
Duration label24 hr
Catalog duration field, when available.
topical Low penetration (~10–20% via stratum corneum) but locally active

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose5 mg
Catalog dose range5 mg - 10 mg
Default routeTopical
Frequency label2× daily
Best time labelMorning under sunscreen, evening as last skincare step.
Food noteN/A — topical.

Catalog protocol note

5–10% Argireline cream applied AM and PM to expression-line areas. Visible results in 4–8 weeks.

Routes and site notes

Available route labelsTopical
Preferred route labelTopical
Common site labelsForehead, Crow's feet, Glabellar lines
Site rotation noteApply to specific expression-line areas; avoid mucous membranes.

Chemistry

SequenceAc-Glu-Glu-Met-Gln-Arg-Arg-NH2
Amino acids6
Molecular formulaC34H60N14O12S
Molecular weight888.99 Da

Vial, reconstitution, and storage

Supply formPre-formulated cream or serum (5–10% concentration)
Typical vial sizeNot listed
DiluentN/A — buy formulated product
Diluent volumeNot listed
Concentration noteConcentration matters: 5–10% in a well-formulated base is the research-supported range.
Before reconstitutionPer product label — usually room temperature; refrigeration extends shelf life.
After reconstitutionN/A — formulated product.
Reconstituted shelf lifeNot listed
Light sensitiveNo
Freeze/thaw warningNo

Safety notes

Common and rare side effects listed in the catalog

  • Generally extremely well-tolerated topically
  • Mild skin irritation (formulation-dependent)
  • Allergic contact dermatitis

Contraindications and warnings

  • Open wounds in application area
  • Effects are subtle — not equivalent to injectable Botox despite marketing.

Other considerations

  • Stack with Matrixyl or peptide complexes for compounded effects.
  • Consistent twice-daily use over 8+ weeks is required for visible results.
  • Cosmetic ingredient — widely available without prescription.

Evidence and regulatory context

Evidence levelCosmetic ingredient with peer-reviewed dermatology studies showing modest line-depth reduction
FDA approvedYes
Regulatory statusFDA-approved cosmetic ingredient
Prescription requiredNo
Approved countriesUS, EU, and most others

Stacking and cycle notes

Stacks well withghk-cu, matrixyl
Avoid combining noteNot listed
Typical cycle labelongoing
Typical break labelNot typically cycled
Cycle guidanceContinuous use; effects regress on discontinuation.

Tracking tips

  • Set realistic expectations — modest line-softening, not Botox-level effect.
  • Apply to clean skin before heavier creams or sunscreen.
  • Pairs well with GHK-Cu and Matrixyl in layered skincare routines.

References

Track it in Peppi

Keep Argireline records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Argireline?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Argireline?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Argireline records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026